Literature DB >> 27903130

Risk factors and mortality in the Carbapenem-resistant Klebsiella pneumoniae infection: case control study.

Fethiye Akgul1, Ilkay Bozkurt1, Mustafa Sunbul1, Saban Esen1, Hakan Leblebicioglu1.   

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) has been known as a nosocomial pathogen, both for the last 10 years in Turkey and for 20 years worldwide. Due to limited treatment options and high mortality rates, despite improvements in the field of medicine at the present time, CRKP is still a big threat for public health. This study was carried out between the dates of January 2010 and September 2014. Patients ≥18 who were hospitalized for at least 72 h and who also had CRKP growth were included in the study as a case group. In the same period patients, who were hospitalized in the same ward and did not have CRKP growth were selected as the control group. It was determined that no glycopeptides and steroids use nor tracheostomy as protective factors would be employed in terms of non-development of CRKP. Mechanical ventilation, tracheostomy, urinary catheter presence, central venous catheterization, nasogastric tube placement, advanced age, acute renal insufficiency, total parenteral nutrition, carbapenem, glycopeptide, and piperacillin tazobactam were all detected as risk factors in terms of CRKP infection development. As a result, rational usage of antibiotics for preventing infections developing with CRKP should be targeted.

Entities:  

Keywords:  Carbapenem-resistant klebsiella pneumoniae; Mortality; Risk factors; klebsiella pneumonia

Mesh:

Substances:

Year:  2016        PMID: 27903130      PMCID: PMC5189867          DOI: 10.1080/20477724.2016.1254976

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  31 in total

Review 1.  Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?

Authors:  G L Daikos; A Markogiannakis
Journal:  Clin Microbiol Infect       Date:  2011-06-02       Impact factor: 8.067

2.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

Review 3.  Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the intensive care unit: a real challenge to physicians, scientific community, and society.

Authors:  Cecilia Godoy Carvalhaes; Rodrigo Cayô; Ana Cristina Gales
Journal:  Shock       Date:  2013-05       Impact factor: 3.454

4.  KPC-producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay: the significance of risk factors for its development and its impact on mortality.

Authors:  Matthaios Papadimitriou-Olivgeris; Markos Marangos; Fotini Fligou; Myrto Christofidou; Christina Sklavou; Sophia Vamvakopoulou; Evangelos D Anastassiou; Kriton S Filos
Journal:  Diagn Microbiol Infect Dis       Date:  2013-07-23       Impact factor: 2.803

5.  Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients.

Authors:  Min-Hyok Jeon; Sang-Ho Choi; Yee Gyung Kwak; Jin-Won Chung; Sang-Oh Lee; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Diagn Microbiol Infect Dis       Date:  2008-11-06       Impact factor: 2.803

6.  Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes.

Authors:  E P Hyle; M J Ferraro; M Silver; H Lee; D C Hooper
Journal:  Infect Control Hosp Epidemiol       Date:  2010-10-28       Impact factor: 3.254

7.  KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin.

Authors:  Derek N Bremmer; Cornelius J Clancy; Ellen G Press; Reem Almaghrabi; Liang Chen; Yohei Doi; M Hong Nguyen; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

8.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case-control study.

Authors:  Diamantis P Kofteridis; Antonis Valachis; Dimitra Dimopoulou; Sofia Maraki; Athanasia Christidou; Elpis Mantadakis; George Samonis
Journal:  J Infect Chemother       Date:  2014-04-03       Impact factor: 2.211

9.  Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Authors:  Mitchell J Schwaber; Shiri Klarfeld-Lidji; Shiri Navon-Venezia; David Schwartz; Azita Leavitt; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

10.  The rising problem of antimicrobial resistance in the intensive care unit.

Authors:  Nele Brusselaers; Dirk Vogelaers; Stijn Blot
Journal:  Ann Intensive Care       Date:  2011-11-23       Impact factor: 6.925

View more
  13 in total

1.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Carbapenem-Resistant Klebsiella pneumoniae in Southwest China: Molecular Characteristics and Risk Factors Caused by KPC and NDM Producers.

Authors:  Zhaoyinqian Li; Zixuan Ding; Jia Yang; Yao Liu; Xinrui Jin; Jingling Xie; Tingting Li; Yinhuan Ding; Zhangrui Zeng; Jinbo Liu
Journal:  Infect Drug Resist       Date:  2021-08-13       Impact factor: 4.003

3.  Association between Antimicrobial Consumption and the Prevalence of Nosocomial Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae in a Tertiary Hospital in Northern Taiwan.

Authors:  Mei-Chun Lee; Hsun Chang; Fang-Ju Sun; Alice Ying-Jung Wu; Chien-Hung Lu; Chun-Ming Lee
Journal:  Am J Trop Med Hyg       Date:  2022-06-13       Impact factor: 3.707

4.  A Pragmatic Machine Learning Model To Predict Carbapenem Resistance.

Authors:  Ryan J McGuire; Sean C Yu; Philip R O Payne; Albert M Lai; M Cristina Vazquez-Guillamet; Marin H Kollef; Andrew P Michelson
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

5.  Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection: A Meta-Analysis.

Authors:  Pin Liu; Xuan Li; Mei Luo; Xuan Xu; Kewen Su; Shuai Chen; Ying Qing; Yingli Li; Jingfu Qiu
Journal:  Microb Drug Resist       Date:  2017-07-27       Impact factor: 3.431

6.  Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods.

Authors:  Stefan E Richter; Loren Miller; Jack Needleman; Daniel Z Uslan; Douglas Bell; Karol Watson; Romney Humphries; James A McKinnell
Journal:  Open Forum Infect Dis       Date:  2019-01-23       Impact factor: 3.835

7.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis.

Authors:  Wei-Min Zhu; Zhe Yuan; Hong-Yu Zhou
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-31       Impact factor: 4.887

8.  Epidemiology of and risk factors for mortality due to carbapenemase-producing organisms (CPO) in healthcare facilities.

Authors:  S Zhao; S Kennedy; M R Perry; J Wilson; M Chase-Topping; E Anderson; M E J Woolhouse; M Lockhart
Journal:  J Hosp Infect       Date:  2021-02-08       Impact factor: 3.926

9.  Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in the intensive care unit.

Authors:  Xia Zheng; Jian-Feng Wang; Wang-Lan Xu; Jun Xu; Juan Hu
Journal:  Antimicrob Resist Infect Control       Date:  2017-10-02       Impact factor: 4.887

Review 10.  Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.

Authors:  Shio-Shin Jean; Yin-Chun Chang; Wei-Cheng Lin; Wen-Sen Lee; Po-Ren Hsueh; Chin-Wan Hsu
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.